Arnold fights records release as part of state audit
'It's disappointing to me that the city is wasting taxpayer money by litigating this issue,' Missouri State Auditor Scott Fitzpatrick said.
Attorney Bob Sweeney, who represents the city, says it has been more than compliant throughout the audit process.
'We've supplied thousands of pages of documents, spent scores of hours obtaining those documents and dozens of hours sitting down face to face,' he said.
The audit has to do with taxpayer funding for transportation projects through what is called Transportation Development Districts (TDD). The auditor is looking at property owned by the TDD as well as the role city officials play while serving on TDD boards.
'When we developed this TDD, we required the property owners to put city officials on the TDD board so that the city officials would have some information and knowledge of what was going on and some say so,' Sweeney said.
Hospice nurse accused of stealing checks from elderly victim
The TDD had collected a tax for a parkway project to run along I-55 south of 141. But that plan was eventually put on hold after people petitioned against it. FOX 2's Chris Hayes reported last year that people wanted to know what was being done with property the city had already purchased for that project. Sweeney told FOX 2 on Wednesday that it is still looking at ways to complete the project without the portions that were objected to by residents.
The auditor says he needs to see more documents from closed city council sessions. However, the City of Arnold has filed a temporary restraining order to try and block the release of unredacted, closed session meetings, citing concerns over significant liability, potential for fraud and loss of public trust for releasing confidential records.
'We access closed records all the time and meeting minutes that would not generally be open records to the public in the state auditor's office. It's a routine thing that we do,' Fitzpatrick said.
The auditor is considering a counter claim if Arnold does not comply with a subpoena for the records. Sweeney said that is not necessary. He simply wants a judge to weigh in on if the unredacted records are subject to release.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
NextEra Energy (NEE) to Invest $120 Billion in Renewables and Storage Through 2029
We recently published . NextEra Energy, Inc. (NYSE:NEE) is one of these profitable utility stocks. NextEra Energy, Inc. (NYSE:NEE), headquartered in Juno Beach, Florida, is a leading North American electric power and energy infrastructure company. It owns Florida Power & Light Company (FPL), serving about 12 million customers, and NextEra Energy Resources, a top U.S. renewable energy developer with a diverse portfolio including natural gas, nuclear, wind, solar, and battery storage. In 2024 and early 2025, NextEra Energy, Inc. (NYSE:NEE) significantly expanded its renewable energy capacity, adding 8.7 gigawatts of new renewable and storage projects in 2024 and 3.2 gigawatts in Q1 2025. FPL also brought 894 megawatts of new solar capacity online, reinforcing the company's clean energy momentum. The business plans to invest approximately $120 billion over the next four years to grow its fleet to around 121 gigawatts, underscoring its long-term commitment to clean energy and infrastructure growth, and strengthening its case as one of the most profitable stocks in the sector. Strategically, the corporation signed a framework agreement with GE Vernova to develop natural gas power generation solutions, broadening its energy mix to meet evolving customer needs and transition goals. Alongside its renewable focus, NextEra Energy, Inc. (NYSE:NEE)'s regulated utility segment continues to provide reliable electricity and stable earnings, supporting its consistent dividend policy. The board recently declared a quarterly dividend of $0.5665 per share payable in September 2025 and expects to raise dividends by about 10% annually through at least 2026, reflecting strong financial health. With a solid cash position of $1.8 billion in Q2 2025 and robust operating cash flow, the corporation is well-positioned for sustained growth and leadership in the clean energy transition. While we acknowledge the potential of NEE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
43 minutes ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Why Wells Fargo Is Confident in Micron's (MU) HBM Growth Story
Micron Technology, Inc. (NASDAQ:MU) is one of the On August 13, Wells Fargo expressed optimism about the stock stating that it is confident in MU's 'ability to achieve / sustain its low / mid-20% HBM market share target in 2H25'. The firm considers Micron's HBM4E logic die customization to be a key differentiator, creating a 'very different business model' where key customers would work with only one or two HBM suppliers on custom solutions. 'We remain confident in MU's ability to achieve / sustain its low / mid-20% HBM market share target in 2H25. We would re-highlight MU's on HBM4E logic die customization as driving a very different business model; believing that key customers would likely work w/ only 1 or 2 HBM suppliers on these custom solutions. HBM4E looks to be a 2027+ story. MU also pointed out its favorable position of utilizing its very mature 1b DRAM process node w/ HBM4, while others (Samsung) are moving to a 1c process.' Micron Technology, Inc. (NASDAQ:MU) develops and sells memory and storage products for data centers, mobile devices, and various industries worldwide. While we acknowledge the potential of MU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
